AT122231T - Use of opium antagonists for the manufacture of a pharmaceutical composition for treatment of alcoholism. - Google Patents

Use of opium antagonists for the manufacture of a pharmaceutical composition for treatment of alcoholism.

Info

Publication number
AT122231T
AT122231T AT89110688T AT89110688T AT122231T AT 122231 T AT122231 T AT 122231T AT 89110688 T AT89110688 T AT 89110688T AT 89110688 T AT89110688 T AT 89110688T AT 122231 T AT122231 T AT 122231T
Authority
AT
Austria
Prior art keywords
opium
alcoholism
antagonists
manufacture
treatment
Prior art date
Application number
AT89110688T
Other languages
German (de)
Inventor
John David Sinclair
Original Assignee
Alko Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US07/205,758 priority Critical patent/US4882335A/en
Application filed by Alko Ltd filed Critical Alko Ltd
Publication of AT122231T publication Critical patent/AT122231T/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22763531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT122231(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/81Addiction
    • Y10S514/811Alcohol
AT89110688T 1988-06-13 1989-06-13 Use of opium antagonists for the manufacture of a pharmaceutical composition for treatment of alcoholism. AT122231T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/205,758 US4882335A (en) 1988-06-13 1988-06-13 Method for treating alcohol-drinking response

Publications (1)

Publication Number Publication Date
AT122231T true AT122231T (en) 1995-05-15

Family

ID=22763531

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89110688T AT122231T (en) 1988-06-13 1989-06-13 Use of opium antagonists for the manufacture of a pharmaceutical composition for treatment of alcoholism.

Country Status (7)

Country Link
US (1) US4882335A (en)
EP (1) EP0346830B1 (en)
AT (1) AT122231T (en)
AU (1) AU609310B2 (en)
CA (1) CA1336962C (en)
DE (2) DE68922525D1 (en)
ES (1) ES2074454T3 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
US5028612A (en) * 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5013740A (en) * 1990-03-22 1991-05-07 Hillel Glover Method for treating emotional numbness and coma
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5298622A (en) * 1993-05-12 1994-03-29 Regents Of The University Of Minnesota Spiroindane opiate analogs
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
US6001848A (en) * 1996-03-25 1999-12-14 The Regents Of The University Of California Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US6203813B1 (en) 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
HU0100310A3 (en) 1997-12-22 2002-11-28 Euro Celtique Sa A method of preventing abuse of opioid dosage forms
RS50070B (en) 1997-12-22 2009-01-22 Euro-Celtique S.A., Oral dosage form comprising a combination of an opioid agonist and naltrexone
WO2001040269A2 (en) * 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
ES2326730T3 (en) 2000-02-08 2009-10-19 Euro-Celtique S.A. Oral formulations of opioid agonists resistant to indebid handling.
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
AU2002305559B2 (en) 2001-05-11 2008-04-03 Mundipharma Pty Limited Abuse-resistant controlled-release opioid dosage form
US7879211B2 (en) * 2001-07-13 2011-02-01 Arkray, Inc. Analyzing instrument, lancet-integrated attachment for concentration measuring device provided with analyzing instrument, and body fluid sampling tool
PT1416842E (en) 2001-07-18 2009-03-31 Euro Celtique Sa Pharmaceutical combinations of oxycodone and naloxone
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
HU0401191A3 (en) 2001-08-06 2006-11-28 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
HU0401022A3 (en) * 2001-08-14 2006-11-28 Biotie Therapies Corp Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse
US20030114475A1 (en) * 2001-10-31 2003-06-19 Addiction Therapies, Inc. Methods for the treatment of addiction
JP4755810B2 (en) 2002-04-05 2011-08-24 ユーロ−セルティーク エス.エイ. Pharmaceutical formulation containing oxycodone and naloxone
MXPA04011875A (en) * 2002-05-31 2005-03-31 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of buprenorphine.
EP2422775A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
WO2004078178A1 (en) * 2003-03-03 2004-09-16 Markus Heilig Buprenorphine compounds for treatment of alcohol dependence and excessive alcohol use
CA2520613C (en) * 2003-03-31 2012-12-04 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20050038062A1 (en) * 2003-04-14 2005-02-17 Burns Lindsay H. Methods and materials for the treatment of pain comprising opioid antagonists
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
WO2004110400A2 (en) * 2003-05-30 2004-12-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
US20050245541A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US20050245461A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US7919499B2 (en) * 2004-04-22 2011-04-05 Alkermes, Inc. Naltrexone long acting formulations and methods of use
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
US7910599B2 (en) 2005-01-10 2011-03-22 John David Sinclair Method for treating eating disorders by selective extinction with transdermal naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20070259939A1 (en) * 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
ES2636657T3 (en) 2006-06-19 2017-10-06 Alpharma Pharmaceuticals Llc pharmaceutical composition
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
ES2618500T3 (en) 2006-10-20 2017-06-21 Neurendo Pharma, Llc Method to restore the incretin effect
FI20070705A (en) 2007-09-14 2009-06-02 Biohit Oyj Binding of acetaldehyde to mouth and stomach
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
RU2522212C2 (en) 2009-03-10 2014-07-10 Еуро-Селтик С.А. Oxicodon and naloxon-containing pharmaceutical compositions with instant release
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
JP2016525138A (en) 2013-07-23 2016-08-22 ユーロ−セルティーク エス.エイ. Oxycodone and naloxone combination for use in the treatment of pain in patients suffering from diseases that cause pain and intestinal dysbiosis and / or diseases that increase the risk for intestinal bacterial transfer
CA2948144A1 (en) * 2014-05-06 2015-11-12 Purdue Pharma L.P. Benzomorphan analogs and use thereof
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
US10034871B2 (en) 2014-11-07 2018-07-31 Regents Of The University Of Minnesota Salts and compositions useful for treating disease
MX2018015985A (en) * 2016-06-24 2019-09-13 Opiant Pharmaceuticals Inc Compositions, devices, and methods for the treatment of alcohol use disorder.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
IE49783B1 (en) * 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene

Also Published As

Publication number Publication date
AU3634889A (en) 1989-12-14
US4882335A (en) 1989-11-21
EP0346830B1 (en) 1995-05-10
AU609310B2 (en) 1991-04-26
DE68922525T2 (en) 1996-01-04
CA1336962C (en) 1995-09-12
ES2074454T3 (en) 1995-09-16
EP0346830A2 (en) 1989-12-20
DE68922525D1 (en) 1995-06-14
EP0346830A3 (en) 1991-09-25

Similar Documents

Publication Publication Date Title
DE69002905T2 (en) A process for the preparation of lipidic microparticles.
DE3587868D1 (en) A process for the preparation of aerogels.
AT95403T (en) A process for the production of dental prostheses.
DE68910718D1 (en) A process for the preparation of taxol.
DE68928783T2 (en) Intermediates for the preparation of fungicides
DE3680989D1 (en) A process for the preparation of solid sustained release nifedipinzusammensetzungen thus obtained compositions.
AT119040T (en) Central cholecystokinin antagonists for the treatment of psychiatric diseases.
DE68919053T2 (en) A process for the preparation of aluminoxanes.
DE3854690T2 (en) A process for the preparation of aluminoxanes.
DE69022557T2 (en) A process for the preparation of copolyestercarbonates.
DE68910145T2 (en) A process for the preparation of azolylmethyl-cyclopentanol derivative.
AT90936T (en) A process for the preparation of 1-aminomethyl-1cyclohexanessigsaeure.
DE68907320D1 (en) A process for the manufacture of modified polypropylene compositions.
DE68902965T2 (en) A process for the preparation of dough.
DE68919358D1 (en) Composition for the treatment of schizophrenia.
DE3435040A1 (en) Pharmaceutical composition suitable for the treatment of hang-over symptoms
DE3761762D1 (en) A process for the preparation of fluoroaliphatic aetherhaltigen carbonylfluoridzusammensetzungen.
DE68927110D1 (en) A process for the preparation of 1,1,1-trifluoro-2,2-dichloroethane
DE3765009D1 (en) A process for the preparation of 4-acetoxy-3-hydroxyethyl-azetidin-2-one derivatives.
DE3585607D1 (en) Use of paroxetine for the preparation of a drug for the treatment of obesity.
DE3876074D1 (en) A process for the preparation of N-phosphonmethylglyzin.
DE69005366T2 (en) Production of I5-polyiodide disinfectant resins.
DE69010444D1 (en) Plant for the production of layers.
DE3886075D1 (en) Use of metformin for the manufacture of medicaments.
DE68911834T2 (en) A process for the preparation of 7-substituted-hept-ene-6-heptanoic and and derivatives thereof.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time